Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that an early-stage compound with a novel mechanism of action could potentially treat all dengue virus...
FDA recently granted Daiichi Sankyo’s Enhertu breakthrough therapy designation in the US to treat adult patients with unresectable or metastatic HER2-positive breast cancer.
Enhertu is an...
ViiV Healthcare recently announced it made a regulatory submission to FDA for approval of a new dispersible tablet regimen for children living with HIV.
The tablet formulation, Triumeq, includes...
Johnson & Johnson recently initiated a Phase 3 clinical trial to study its RSV vaccine's efficacy, safety, and immunogenicity against lower respiratory tract disease (LRTD) in adults.
The...
FDA recently approved Amgen’s Repatha to treat pediatric patients ten and older with autosomal dominant disease, heterozygous familial hypercholesterolemia (HeFH), to reduce low-density...
Francis S. Collins, MD, PhD, will be stepping down as director of the National Institutes of Health (NIH) by the end of 2021.
Collins is the longest-serving presidentially appointed NIH director,...
Johnson & Johnson recently announced that Xarelto elicited fewer blood clots and clinical events strongly associated with blood clots in pediatric patients compared to treatment with aspirin.
The...
Eli Lilly and Company recently announced it will lower the list price of Insulin Lispro Injection in the US by another 40 percent.
Effective January 1, 2022, the new list price will be $82.41 for...
FDA recently approved Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Value to improve therapy options for individuals with mitral or aortic valve disease.
The next-generation devices...
AstraZeneca and VaxEquity recently collaborated to discover, develop, and commercialize a self-amplifying RNA (saRNA) therapeutics platform.
The long-term research collaboration aims to optimize...
Roche recently announced that Tecentriq elicited disease-free survival in patients with Stage II-IIA non-small cell lung cancer (NSCLC).
Data from the IMpower010 trial, published in The Lancet, found...
SAS and the University of North Carolina at Chapel Hill (UNC-Chapel Hill) recently partnered to transform the antiviral drug development process and prevent infectious disease threats from turning into...
AbbVie and Regenxbio recently partnered to develop and commercialize RGX-314, a potential one-time gene therapy to treat various chronic retinal diseases.
Researchers are currently evaluating...
FDA recently approved Samsung Bioepis and Biogen’s Byooviz as the first biosimilar to Lucentis to treat several eye diseases and conditions.
Byooviz is approved to treat neovascular (wet)...
Thermo Fisher Scientific recently launched single, fully-automated enzyme analyzers designed specifically for enzyme assay applications.
The Thermo Scientific Gallery Enzyme Master and Thermo...
Johnson & Johnson recently announced that its Ebola vaccine regimen, Zabdeno and Mvabea, generated robust antibody immune responses in children and adults.
The Phase 3 EBOVAC-Salone clinical...
FDA recently granted Breakthrough Designation for Eli Lilly & Company and Boehringer Ingelheim’s diabetes drug, Jardiance, as an investigational treatment for adults with heart failure with...
Many experts expect immunotherapy to positively impact the treatment landscape for patients with earlier-stage cancers in the neoadjuvant, adjuvant, and perioperative settings, according to a new...
